High-dose chemotherapy with autologous stem cell rescue (HDCT) is a potential treatment for stage III HER2-negative breast cancer patients with homologous recombination-deficient (HRD) tumours [1–3]. This evidence concerns the gene ERBB2 and breast carcinoma.